|
ES2258793T5
(es)
*
|
1996-05-24 |
2010-01-25 |
Biogen Idec Ma Inc. |
Moduladores de la regeneracion tisular.
|
|
ATE425249T1
(de)
*
|
2000-06-16 |
2009-03-15 |
Biogen Idec Inc |
Renale regulatorische elemente und deren verwendung
|
|
DK1401869T3
(da)
*
|
2001-06-01 |
2008-04-28 |
Biogen Idec Inc |
Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
|
|
US8709412B2
(en)
*
|
2001-06-29 |
2014-04-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of TIM receptor activity in combination with cytoreductive therapy
|
|
US7470428B2
(en)
*
|
2002-01-30 |
2008-12-30 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
|
|
EP2025345A1
(en)
*
|
2002-12-30 |
2009-02-18 |
Biogen Idec MA Inc. |
KIM-1 antagonists and use to modulate immune system
|
|
CA2541006C
(en)
*
|
2003-10-03 |
2015-02-17 |
Brigham And Women's Hospital |
Tim-3 polypeptides
|
|
TW200539890A
(en)
*
|
2004-03-12 |
2005-12-16 |
Brigham & Womens Hospital |
Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
|
|
KR20070037570A
(ko)
*
|
2004-03-24 |
2007-04-05 |
텔로스 파마슈티칼스 인코포레이티드 |
백신에 대한 면역반응을 향상시키는 보강제로서의 조성물및 이의 사용 방법
|
|
WO2005095594A1
(fr)
*
|
2004-03-31 |
2005-10-13 |
Universite De La Mediterranee |
Glycopeptides derives de structures pancreatiques, anticorps et leurs applications en diagnostic et therapeutique
|
|
JP2008506637A
(ja)
*
|
2004-06-14 |
2008-03-06 |
ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ |
胎児起源の細胞に対する抗体
|
|
KR101213894B1
(ko)
*
|
2005-03-02 |
2012-12-20 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Ｔｈ2 매개성 병태를 치료하기 위한 ｋｉｍ-1 항체
|
|
EP2081961A2
(en)
*
|
2006-11-15 |
2009-07-29 |
The Brigham and Women's Hospital, Inc. |
Therapeutic uses of tim-3 modulators
|
|
EP2212350B1
(en)
*
|
2007-10-26 |
2013-08-28 |
Governing Council of the University of Toronto |
Treating chronic viral infection by targetting TIM-3
|
|
WO2009097394A2
(en)
*
|
2008-01-29 |
2009-08-06 |
The Brigham And Women's Hospital, Inc. |
Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
|
|
JP5748653B2
(ja)
|
2009-04-10 |
2015-07-15 |
協和発酵キリン株式会社 |
抗ｔｉｍ−３抗体を用いた血液腫瘍治療法
|
|
AU2011262758B8
(en)
*
|
2010-06-11 |
2014-09-04 |
Kyowa Kirin Co., Ltd. |
Anti-tim-3 antibody
|
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
|
WO2013006490A2
(en)
*
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
WO2014022332A1
(en)
|
2012-07-31 |
2014-02-06 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
|
WO2014151648A1
(en)
*
|
2013-03-15 |
2014-09-25 |
Coronado Biosciences, Inc. |
Treatment of autoimmune disease using helminthic parasites
|
|
WO2015003114A1
(en)
|
2013-07-05 |
2015-01-08 |
University Of Washington Through Its Center For Commercialization |
Soluble mic neutralizing monoclonal antibody for treating cancer
|
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
PE20170255A1
(es)
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
HUE045065T2
(hu)
|
2014-01-31 |
2019-12-30 |
Novartis Ag |
TIM-3 antitest molekulák és felhasználásaik
|
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
SI3148579T1
(sl)
|
2014-05-28 |
2021-07-30 |
Agenus Inc. |
Proti GITR antitelesa in postopki z njihovo uporabo
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
SI3215532T1
(sl)
*
|
2014-11-06 |
2020-02-28 |
F. Hoffmann-La Roche Ag |
Protitelesa proti TIM3 in postopki uporabe
|
|
EP4141032B1
(en)
|
2014-11-20 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
|
|
EP3265486A4
(en)
*
|
2015-03-06 |
2018-11-14 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind tim3
|
|
FI3277321T3
(fi)
*
|
2015-04-01 |
2024-10-31 |
Anaptysbio Inc |
T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
|
|
CA2985350A1
(en)
*
|
2015-05-08 |
2016-11-17 |
Wilson Wolf Manufacturing |
Improved culture methods and devices for testing
|
|
TW201713332A
(zh)
|
2015-07-14 |
2017-04-16 |
協和醱酵麒麟有限公司 |
包含與抗體組合投予之ｉｄｏ抑制物之腫瘤治療劑
|
|
HRP20211058T8
(hr)
|
2015-07-29 |
2021-11-26 |
Novartis Ag |
Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
|
WO2017055484A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for determining the metabolic status of lymphomas
|
|
JP6981973B2
(ja)
*
|
2015-10-01 |
2021-12-17 |
ヒート バイオロジクス，インコーポレイテッド |
Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法
|
|
WO2017055404A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for pd1 and tim3
|
|
CN108883173B
(zh)
|
2015-12-02 |
2022-09-06 |
阿吉纳斯公司 |
抗体和其使用方法
|
|
EP3400443B1
(en)
|
2016-01-04 |
2020-09-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
|
|
EP3464360B1
(en)
|
2016-05-27 |
2025-11-12 |
Agenus Inc. |
Anti-tim-3 antibodies and methods of use thereof
|
|
WO2017214943A1
(zh)
*
|
2016-06-16 |
2017-12-21 |
毛侃琅 |
促进 tim-3 基因表达的慢病毒表达载体及其应用
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
CN109757103B
(zh)
|
2016-07-14 |
2024-01-02 |
百时美施贵宝公司 |
针对tim3的抗体及其用途
|
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
JOP20190013A1
(ar)
|
2016-08-25 |
2019-01-31 |
Lilly Co Eli |
أجسام مضادة لـ (تي آي ام -3)
|
|
US11203637B2
(en)
*
|
2016-08-26 |
2021-12-21 |
Beigene, Ltd. |
Anti-Tim-3 antibodies and use thereof
|
|
MX2019005116A
(es)
|
2016-11-01 |
2019-11-12 |
Anaptysbio Inc |
Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3).
|
|
US11672771B2
(en)
|
2016-11-04 |
2023-06-13 |
Aximmune, Inc. |
Beta-alethine, immune modulators, and uses thereof
|
|
JOP20190133A1
(ar)
|
2016-12-08 |
2019-06-02 |
Innovent Biologics Suzhou Co Ltd |
أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
|
|
EP3565596A4
(en)
|
2017-01-05 |
2020-12-16 |
Brown University |
PROCESSES AND COMPOSITIONS RELATING TO ANTI-CHI3LI ANTIBODY REAGENTS
|
|
WO2018129553A1
(en)
|
2017-01-09 |
2018-07-12 |
Tesaro, Inc. |
Methods of treating cancer with anti-tim-3 antibodies
|
|
JP7325045B2
(ja)
|
2017-02-27 |
2023-08-14 |
カイロス セラピューティクス， インコーポレイテッド |
癌を処置する抗体コンストラクトおよび方法
|
|
US20210186982A1
(en)
|
2017-03-24 |
2021-06-24 |
Universite Nice Sophia Antipolis |
Methods and compositions for treating melanoma
|
|
MY201482A
(en)
|
2017-04-03 |
2024-02-26 |
Hoffmann La Roche |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
EP4516809A3
(en)
|
2017-04-05 |
2025-09-03 |
F. Hoffmann-La Roche AG |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
JP7257967B2
(ja)
|
2017-05-01 |
2023-04-14 |
ザ チルドレンズ メディカル センター コーポレーション |
抗ｐｄ１抗体試薬に関する方法および組成物
|
|
US20200197389A1
(en)
*
|
2017-05-12 |
2020-06-25 |
The Regents Of The University Of California |
Methods for detecting dysbiosis and treating subjects with dysbiosis
|
|
CA3066747A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
|
EP4039274A1
(en)
|
2017-07-28 |
2022-08-10 |
Phanes Therapeutics, Inc. |
Anti-tim-3 antibodies and uses thereof
|
|
CA3072087A1
(en)
|
2017-08-11 |
2019-02-14 |
Board Of Regents, The University Of Texas System |
Targeting kinases for the treatment of cancer metastasis
|
|
AU2018360389B2
(en)
|
2017-11-06 |
2024-09-19 |
Aurigene Oncology Limited |
Conjoint therapies for immunomodulation
|
|
EP3735590A1
(en)
|
2018-01-04 |
2020-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
|
EP3740506A1
(en)
|
2018-01-16 |
2020-11-25 |
Bristol-Myers Squibb Company |
Methods of treating cancer with antibodies against tim3
|
|
EP3756012A1
(en)
|
2018-02-21 |
2020-12-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
|
|
US11643438B2
(en)
|
2018-07-20 |
2023-05-09 |
The Board Of Regents Of The University Of Oklahoma |
Antimicrobial peptides and methods of use
|
|
CN110655566B
(zh)
*
|
2018-10-25 |
2021-06-18 |
浙江大学 |
可溶性Tim-3重组蛋白及其突变型蛋白的制备和应用
|
|
US20230183379A1
(en)
|
2018-11-20 |
2023-06-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
WO2020120592A1
(en)
|
2018-12-12 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating melanoma
|
|
EP3898699A1
(en)
|
2018-12-19 |
2021-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
|
|
EP3897648B1
(en)
|
2018-12-20 |
2023-08-23 |
Novartis AG |
Extended low dose regimens for mdm2 inhibitors
|
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
|
ES3033655T3
(en)
|
2019-01-30 |
2025-08-06 |
Inst Nat Sante Rech Med |
Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
|
|
EP3921031A1
(en)
|
2019-02-04 |
2021-12-15 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for modulating blood-brain barrier
|
|
EP3924520A1
(en)
|
2019-02-13 |
2021-12-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
|
|
CN113473979B
(zh)
|
2019-02-28 |
2024-09-27 |
爱默蕾大学 |
双缩二胍化合物、药物组合物和在管理癌症中的用途
|
|
EP3963109A1
(en)
|
2019-04-30 |
2022-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
WO2020227431A1
(en)
|
2019-05-06 |
2020-11-12 |
Brown University |
Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells
|
|
US12377063B2
(en)
|
2019-07-11 |
2025-08-05 |
Emory University |
Combination therapies for managing cancer
|
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
WO2021053490A1
(en)
|
2019-09-16 |
2021-03-25 |
Novartis Ag |
Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis
|
|
WO2021064180A1
(en)
|
2019-10-03 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
|
WO2021074391A1
(en)
|
2019-10-17 |
2021-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing nasal intestinal type adenocarcinomas
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
EP4051286A1
(en)
|
2019-10-29 |
2022-09-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for treating uveal melanoma
|
|
CN114599372A
(zh)
|
2019-11-04 |
2022-06-07 |
阿斯利康(瑞典)有限公司 |
用于治疗癌症的组合疗法
|
|
EP4076508A1
(en)
|
2019-12-19 |
2022-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and vaccine compositions to treat cancers
|
|
US20230076415A1
(en)
|
2020-01-17 |
2023-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
EP4100126A1
(en)
|
2020-02-05 |
2022-12-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
|
|
WO2021170777A1
(en)
|
2020-02-28 |
2021-09-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, prognosing and managing treatment of breast cancer
|
|
US20230266332A1
(en)
|
2020-07-28 |
2023-08-24 |
Inserm (Institut National De La Santè Et De La Recherch Médicale) |
Methods and compositions for preventing and treating a cancer
|
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
|
US20230416838A1
(en)
|
2020-11-16 |
2023-12-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
US20230416830A1
(en)
|
2020-11-16 |
2023-12-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
US20240165094A1
(en)
|
2021-03-17 |
2024-05-23 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating melanoma
|
|
EP4326903A1
(en)
|
2021-04-23 |
2024-02-28 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
|
EP4326773A4
(en)
|
2021-04-23 |
2025-09-24 |
Suzhou Neologics Bioscience Co Ltd |
ANTIBODIES TARGETING TIM-3 AND THEIR USES
|
|
US20240426823A1
(en)
|
2021-11-03 |
2024-12-26 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
|
EP4452257A1
(en)
|
2021-12-21 |
2024-10-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
AU2023314782A1
(en)
|
2022-07-27 |
2025-01-30 |
Umoja Biopharma, Inc. |
Differentiation of stem cells in suspension culture
|
|
EP4568670A1
(en)
|
2022-08-10 |
2025-06-18 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
|
US20260061031A1
(en)
|
2022-09-14 |
2026-03-05 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
|
|
EP4605000A1
(en)
|
2022-10-21 |
2025-08-27 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
|
EP4608390A1
(en)
|
2022-10-24 |
2025-09-03 |
Cancer Research Technology Limited |
Tumour sensitisation to checkpoint inhibitors with redox status modifier
|
|
EP4608995A1
(en)
|
2022-10-24 |
2025-09-03 |
Memorial Sloan-Kettering Cancer Center |
Tumour stratification for responsiveness to an immune checkpoint inhibitor
|
|
EP4649173A1
(en)
|
2023-01-13 |
2025-11-19 |
Akrivia Biomedics Limited |
Method of profiling diseases
|
|
WO2024161015A1
(en)
|
2023-02-03 |
2024-08-08 |
Institut National de la Santé et de la Recherche Médicale |
Method to treat age-related diseases
|
|
EP4689658A1
(en)
|
2023-03-28 |
2026-02-11 |
Institut National de la Santé et de la Recherche Médicale |
Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
|
|
WO2024231384A1
(en)
|
2023-05-10 |
2024-11-14 |
Institut National de la Santé et de la Recherche Médicale |
Compositions for treating senescence related disease
|
|
EP4713371A1
(en)
|
2023-05-17 |
2026-03-25 |
Institut National de la Santé et de la Recherche Médicale |
Anti-cathepsin-d antibodies
|
|
WO2024245951A1
(en)
|
2023-05-26 |
2024-12-05 |
Institut National de la Santé et de la Recherche Médicale |
Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
|
|
WO2024256635A1
(en)
|
2023-06-15 |
2024-12-19 |
Institut National de la Santé et de la Recherche Médicale |
Dpm1 inhibitor for treating cancer
|
|
WO2025068180A1
(en)
|
2023-09-25 |
2025-04-03 |
Institut National de la Santé et de la Recherche Médicale |
Methods of treatment of cancer by targetting cancer - associated fibroblasts
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
WO2025078632A1
(en)
|
2023-10-12 |
2025-04-17 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from cancer
|
|
WO2025132479A1
(en)
|
2023-12-18 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Flt3 inhibitor for modulating macrophages polarization
|
|
WO2025132770A1
(en)
|
2023-12-22 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Affitins for the treatment of cancer
|
|
WO2025210123A1
(en)
|
2024-04-03 |
2025-10-09 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for treating cancers
|
|
WO2025219330A1
(en)
|
2024-04-15 |
2025-10-23 |
Institut National de la Santé et de la Recherche Médicale |
Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
|
|
WO2025228998A1
(en)
|
2024-04-30 |
2025-11-06 |
Institut National de la Santé et de la Recherche Médicale |
Use of hdac4 inhibitors for the treatment of melanoma
|
|
WO2025247829A1
(en)
|
2024-05-27 |
2025-12-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for treating prostate cancer
|
|
NL2037811B1
(en)
|
2024-05-29 |
2025-12-12 |
Univ Oslo |
Treatment for Cancer
|
|
GB202408360D0
(en)
|
2024-06-11 |
2024-07-24 |
Cancer Research Tech Ltd |
Tumour sensitisation
|
|
WO2026013071A1
(en)
|
2024-07-09 |
2026-01-15 |
Institut National de la Santé et de la Recherche Médicale |
Setdb1 inhibitor for use in the treatment of uveal melanoma
|